Skip to main content
Janssen is now J&J Innovative Medicine.    |  
 
VISIT JANSSEN GLOBAL
 
 
 

US
change location▼

Search
Search

Welcome to Janssen United States

VISIT JANSSEN GLOBAL

Home › Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression